Nurse-led management of uncontrolled hypertension in those with diabetes and high vascular risk. The outcomes of the Wolverhampton protocol

Practical Diabetes International

Volumn 24, Issue 2, 2007, Pages 92-96

  Singh, P K ^a,b   Beach, P ^b   Iqbal, N ^c   Buch, H N ^b   Singh, Baldev M ^b  

^a QUEEN S HOSPITAL   (United Kingdom)

^b NEW CROSS HOSPITAL   (United Kingdom)

^c KING S MILL HOSPITAL   (United Kingdom)

Author keywords

Blood pressure; High risk; Nurse led clinic

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; CHOLESTEROL; DILTIAZEM; DOXAZOSIN; FELODIPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOSARTAN; ORAL ANTIDIABETIC AGENT; RAMIPRIL; SLOZEM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COUGHING; DIABETES MELLITUS; DIABETIC HYPERTENSION; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; EDEMA; ELECTROLYTE DISTURBANCE; FEMALE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MEDICAL AUDIT; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSING CARE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIMARY PREVENTION; RISK ASSESSMENT; SIDE EFFECT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE;

EID: 35648980636     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1062     Document Type: Article

References (18)

1. The Hypertension in Diabetes Study group. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 Diabetes: UKPDS 38. BMJ 1998; 317:703-713.
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results from the Hypertension Optimal Treatment (HOT) randomised trial. HOT study group. Lancet 1998; 351: 1755-1762.
4. Joseph F, Younis N, Sowery J, et al. Blood pressure control in diabetes: are we achieving the guideline targets? Pract Diabetes Int 2003; 20: 276-282.
5. Jayawarna CA, Gandhi R, Thomson GA, et al. Inadequate use of evidence based doses of ramipril in type 2 diabetic patients with hypertension: HOPE for better results. Pract Diabetes Int 2005; 22: 161-163.
6. What care to expect. http://www.wdconline.org.uk [accessed 6 July 2006].
7. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
8. Williams B, Poulter NR, Brown MJ, et al. Guidelines for Management of Hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185.
9. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003; 362: 1527-1545.
10. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular Disease Risk Profiles. Am Heart J 1990; 121: 293-298.
11. New JP, Mason MJ, Freemantle N, et al. Specialist nurse-led intervention to treat and control hypertension and hyperlipidaemia in diabetes (SPLINT). Diabetes Care 2003; 26: 2250-2255.
12. Denver EM, Barnard M, Woolfson RG, et al. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with Type 2 Diabetes. Diabetes Care 2003; 26: 2256-2260.
13. Woodward A, Wallymahmed M, Wilding J, et al. Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabetic Med 2006; 23: 780-787.
14. Woodward A, Wallymahmed M, Wilding J, et al. Improved glycaemic control - an unintended benefit of a nurse-led cardiovascular risk reduction clinic. Diabetic Med 2005; 22: 1272-1274.
15. Yeo WW, Yeo R. Predicting CHD risk in patients with diabetes mellitus. Diabetic Med 2001; 18: 341-344.
16. Gerstein HC, Mann JF, Yi Q et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and non-diabetic individuals. JAMA 2001; 286: 421-426.
17. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomised trial. Ann Intern Med 2001; 134: 629-636.
18. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial. JAMA 2002; 288: 2981-2997.